Kevin Scott Landau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kevin Scott Landau has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Chakra Pani Chaulagain
Department of Hematology and Oncology Cleveland Clinic Florida Weston Florida USA
3 shared publications - Chieh-Lin Fu
Department of Hematology and Oncology Cleveland Clinic Florida Weston Florida USA
3 shared publications - Hong Liang
Department of Botany and Plant Sciences, University of California , Riverside, CA 92521 , USA
2 shared publications - Insung Na
Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
2 shared publications - Ryan O. Schenck
Integrated Mathematical Oncology Department, H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA
2 shared publications - Ana M. Santander
Division of Gastroenterology, Department of Medicine, University of Miami-Leonard Miller School of Medicine, Miami, Florida
1 shared publication
Latest Publications
- Open Access
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 9333-9334
Determinants of Overall Survival (OS) of Waldenstrom Macroglobulinemia (WM): A National Cancer Database (NCDB) Analysis of over 14,000 Patients Treated between Years 2004 and 2017
Introduction: Real world outcome data for Waldenstrom Macroglobulinemia (WM) is limited due to relatively rare and indolent nature of this B cell Non-Hodgkin ly
- 15 November 2022
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 9333-9334
Open AccessDeterminants of Overall Survival (OS) of Waldenstrom Macroglobulinemia (WM): A National Cancer Database (NCDB) Analysis of over 14,000 Patients Treated between Years 2004 and 2017
Introduction: Real world outcome data for Waldenstrom Macroglobulinemia (WM) is limited due to relatively rare and indolent nature of this B cell Non-Hodgkin ly
- 1 June 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (16_suppl) , 8066
Determinants of overall survival (OS) of primary plasma cell leukemia (pPCL): A National Cancer Database (NCDB) analysis of years 2004 to 2009.
8066 Background: Outcome data for pPCL is limited due to the rare & aggressive nature of the disease. In this retrospective analysis, we utilized NCDB to identify factors contributing to 1 & 5-year OS of pPCL patients treated at CoC-accredited facilities across USA. Methods: Using the NCDB, we identified N= 325 pPCL patients diagnosed between 2004-2009 after excluding entries missing relevant values. Univariate analysis was used to summarize & assess the potential survival factors individually & multivariate Cox regression analysis with backward elimination (using significance level of p<0.05) was utilized to identify the independent survival factors. Kaplan-Meier (KM) survival curves of patient cohort were also produced. SAS version 9.4 was used to analyze the data. Results: Multivariate Cox regression analysis with backward elimination method revealed that there were 4 significant independent survival factors including sex, Charlson-Deyo Comorbidity Index (CCI), facility type, and insurance, while age & year-of-diagnosis were not independent survival factors (Table). Male patients were more likely to die compared to female patients (HR=1.40, p=0.005); patients with CCI ≥1 had higher chance to suffer death compared to patients with CCI= 0 (HR=1.52, p=0.002); patients not treated at an academic center (AC) had lower survival compared to those treated at ACs (HR=1.35, p=0.001); and patients without private insurance (PI) were more likely to suffer death compared to those with PI (HR=1.54, p=0.001). The 1 & 5-year survival rates for whole cohort were 51.3% (95%CI: 45.8%-56.8%), and 18.9% (95%CI: 14.6%-23.2%) using KM estimate, respectively. Only 6/325 =1.8% patients underwent autologous hematopoietic stem cell transplant (HSCT). Detailed analysis will be presented. Conclusions: In this large analysis of pPCL patients, we identified that being female, having less comorbidities, getting treatment at ACs, and having PI had significantly greater OS. Overall, pPCL is associated with low survival rates both at 1 & 5-years and HSCT may be enormously under-utilized for pPCL patients in the real world setting.
- 1 June 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (16_suppl) , 8066
Determinants of overall survival (OS) of primary plasma cell leukemia (pPCL): A National Cancer Database (NCDB) analysis of years 2004 to 2009.
8066 Background: Outcome data for pPCL is limited due to the rare & aggressive nature of the disease. In this retrospective analysis, we utilized NCDB to identify factors contributing to 1 & 5-year OS of pPCL patients treated at CoC-accredited facilities across USA. Methods: Using the NCDB, we identified N= 325 pPCL patients diagnosed between 2004-2009 after excluding entries missing relevant values. Univariate analysis was used to summarize & assess the potential survival factors individually & multivariate Cox regression analysis with backward elimination (using significance level of p<0.05) was utilized to identify the independent survival factors. Kaplan-Meier (KM) survival curves of patient cohort were also produced. SAS version 9.4 was used to analyze the data. Results: Multivariate Cox regression analysis with backward elimination method revealed that there were 4 significant independent survival factors including sex, Charlson-Deyo Comorbidity Index (CCI), facility type, and insurance, while age & year-of-diagnosis were not independent survival factors (Table). Male patients were more likely to die compared to female patients (HR=1.40, p=0.005); patients with CCI ≥1 had higher chance to suffer death compared to patients with CCI= 0 (HR=1.52, p=0.002); patients not treated at an academic center (AC) had lower survival compared to those treated at ACs (HR=1.35, p=0.001); and patients without private insurance (PI) were more likely to suffer death compared to those with PI (HR=1.54, p=0.001). The 1 & 5-year survival rates for whole cohort were 51.3% (95%CI: 45.8%-56.8%), and 18.9% (95%CI: 14.6%-23.2%) using KM estimate, respectively. Only 6/325 =1.8% patients underwent autologous hematopoietic stem cell transplant (HSCT). Detailed analysis will be presented. Conclusions: In this large analysis of pPCL patients, we identified that being female, having less comorbidities, getting treatment at ACs, and having PI had significantly greater OS. Overall, pPCL is associated with low survival rates both at 1 & 5-years and HSCT may be enormously under-utilized for pPCL patients in the real world setting.
- 24 October 2020
- Published by Elsevier in Gastroenterology
- Vol. 160 (3) , 797-808.e6
Epithelial TLR4 Signaling Activates DUOX2 to Induce Microbiota-Driven Tumorigenesis
- 24 October 2020
- Published by Elsevier in Gastroenterology
- Vol. 160 (3) , 797-808.e6
Epithelial TLR4 Signaling Activates DUOX2 to Induce Microbiota-Driven Tumorigenesis
- 28 February 2017
- Published by Bentham Science Publishers Ltd. in Current Protein & Peptide Science
- Vol. 18 (5) , 453-481
Highly Disordered Proteins in Prostate Cancer
Prostate cancer is one of the major threats to the man’s health. There are several mechanisms of the prostate cancer development characterized by the involvement of various androgen-related and androgen-unrelated factors in prostate cancer pathogenesis and in the metastatic carcinogenesis of prostate. In all these processes, proteins play various important roles, and the KEGG database has information on 88 human proteins experimentally shown to be involved in prostate cancer. It is known that many proteins associated with different human maladies are intrinsically disordered (i.e., they do not have stable secondary and/or tertiary structure in their unbound states). The goal of this review is to consider several highly disordered proteins known to be associated with the prostate cancer pathogenesis in order to better understand the roles of disordered proteins in this disease. We also hope that consideration of the pathology-related proteins from the perspective of intrinsic disorder can potentially lead to future experimental studies of these proteins to find novel pathways associated with prostate cancer.
- 28 February 2017
- Published by Bentham Science Publishers Ltd. in Current Protein & Peptide Science
- Vol. 18 (5) , 453-481
Highly Disordered Proteins in Prostate Cancer
Prostate cancer is one of the major threats to the man’s health. There are several mechanisms of the prostate cancer development characterized by the involvement of various androgen-related and androgen-unrelated factors in prostate cancer pathogenesis and in the metastatic carcinogenesis of prostate. In all these processes, proteins play various important roles, and the KEGG database has information on 88 human proteins experimentally shown to be involved in prostate cancer. It is known that many proteins associated with different human maladies are intrinsically disordered (i.e., they do not have stable secondary and/or tertiary structure in their unbound states). The goal of this review is to consider several highly disordered proteins known to be associated with the prostate cancer pathogenesis in order to better understand the roles of disordered proteins in this disease. We also hope that consideration of the pathology-related proteins from the perspective of intrinsic disorder can potentially lead to future experimental studies of these proteins to find novel pathways associated with prostate cancer.
- Open Access
- 1 January 2016
- Published by Wolters Kluwer Health in Asian Journal of Andrology
- Vol. 18 (5) , 662-672
Unfoldomics of prostate cancer: on the abundance and roles of intrinsically disordered proteins in prostate cancer
Prostatic diseases such as prostate cancer and benign prostatic hyperplasia are highly prevalent among men. The number of studies focused on the abundance and roles of intrinsically disordered proteins in prostate cancer is rather limited. The goal of this study is to analyze the prevalence and degree of disorder in proteins that were previously associated with the prostate cancer pathogenesis and to compare these proteins to the entire human proteome. The analysis of these datasets provides means for drawing conclusions on the roles of disordered proteins in this common male disease. We also hope that the results of our analysis can potentially lead to future experimental studies of these proteins to find novel pathways associated with this disease.
- 1 January 2016
- Published by Wolters Kluwer Health in Asian Journal of Andrology
- Vol. 18 (5) , 662-672
Open AccessUnfoldomics of prostate cancer: on the abundance and roles of intrinsically disordered proteins in prostate cancer
Prostatic diseases such as prostate cancer and benign prostatic hyperplasia are highly prevalent among men. The number of studies focused on the abundance and roles of intrinsically disordered proteins in prostate cancer is rather limited. The goal of this study is to analyze the prevalence and degree of disorder in proteins that were previously associated with the prostate cancer pathogenesis and to compare these proteins to the entire human proteome. The analysis of these datasets provides means for drawing conclusions on the roles of disordered proteins in this common male disease. We also hope that the results of our analysis can potentially lead to future experimental studies of these proteins to find novel pathways associated with this disease.